Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

bioAffinity Technologies, Inc. Director's Dealing 2022

Dec 5, 2022

35439_dirs_2022-12-05_602a9cfc-359f-4d57-b9bd-793de2447f2a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2022-08-29

Reporting Person: Zannes Timothy P (Secretary, EVP, Gen. Counsel)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $1.16 2024-04-28 Common Stock (64848) Direct
Stock Option (right to buy) $7.00 2027-04-24 Common Stock (1428) Direct
Stock Option (right to buy) $7.70 2028-05-07 Common Stock (4285) Direct
Stock Option (right to buy) $7.70 2029-02-25 Common Stock (2142) Direct
Stock Option (right to buy) $7.70 2030-02-05 Common Stock (2142) Direct
Stock Option (right to buy) $7.70 2031-07-26 Common Stock (2142) Direct

Footnotes

F1: The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering.

F2: Represents a right to purchase 64,848 shares of Common Stock upon exercise of a ten-year option granted to Mr. Zannes under the Issuer's 2014 Equity Incentive Plan (the "EIP") on April 28, 2014. This option vested in 7 monthly installments beginning on May 28, 2014 and is fully vested and exercisable as of the date of this report.

F3: Represents a right to purchase 1,428 shares of Common Stock upon exercise of a ten-year option granted to Mr. Zannes under the EIP on April 24, 2017. This option vested in 12 monthly installments beginning on May 24, 2017 and is fully vested and exercisable as of the date of this report.

F4: Represents a right to purchase 4,285 shares of Common Stock upon exercise of a ten-year option granted to Mr. Zannes under the EIP on May 7, 2018. This option vested in 12 monthly installments beginning on June 7, 2018 and is fully vested and exercisable as of the date of this report.

F5: Represents a right to purchase 2,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Zannes under the EIP on February 25, 2019. This option vested in 12 monthly installments beginning on March 25, 2019 and is fully vested and exercisable as of the date of this report.

F6: Represents a right to purchase 2,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Zannes under the EIP on February 5, 2020. This option vested in 12 monthly installments beginning on March 5, 2020 and is fully vested and exercisable as of the date of this report.

F7: Represents a right to purchase 2,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Zannes under the EIP on July 26, 2021. This option vested in 12 monthly installments beginning on August 26, 2021 and is fully vested and exercisable as of the date of this report.